Nutritional Deficiencies in Critical Illness

Quick Answer

Nutritional deficiencies are highly prevalent in critically ill patients (30-80%), arising from inadequate intake, increased metabolic demand, redistribution, and enhanced losses. Thiamine deficiency causes Type B lactic acidosis, Wernicke encephalopathy, and wet beriberi cardiac failure - requiring empiric treatment before dextrose in high-risk patients. Vitamin C depletion occurs rapidly in sepsis but high-dose supplementation (LOVIT trial) showed harm. Vitamin D deficiency is common (40-80%) but routine supplementation (VITdAL-ICU, VIOLET) shows no mortality benefit. Refeeding syndrome is a life-threatening complication of nutritional initiation in malnourished patients, characterized by hypophosphatemia, hypokalemia, hypomagnesemia, and thiamine depletion. Prevention requires thiamine supplementation, electrolyte correction, and "start low, go slow" feeding protocols.

---

CICM Exam Focus

SAQ Likely Stems

• "Describe the pathophysiology and management of thiamine deficiency in a patient with unexplained lactic acidosis"
• "Outline the prevention and management of refeeding syndrome in a malnourished ICU patient"
• "Critically evaluate the evidence for vitamin C supplementation in sepsis"
• "Describe the assessment of nutritional status in critically ill patients"

Hot Case Presentations

• Chronic alcohol user with persistent lactic acidosis despite resuscitation
• Malnourished patient (BMI <16) requiring enteral nutrition initiation
• Long-stay ICU patient with poor wound healing and immune dysfunction
• Septic shock patient with discussion of metabolic resuscitation strategies

Viva Topics

• Thiamine biochemistry and clinical syndromes (Wernicke, wet/dry beriberi)
• Evidence for vitamin C in sepsis (CITRIS-ALI, VITAMINS, LOVIT)
• Vitamin D trials (VITdAL-ICU, VIOLET) - why no benefit?
• NICE refeeding syndrome criteria and prevention protocols
• Nutritional assessment tools (SGA, NUTRIC, NRS-2002)
• Micronutrient monitoring in RRT and parenteral nutrition

---

Key Points

1. Thiamine deficiency occurs in 20-70% of critically ill patients and causes Type B lactic acidosis via pyruvate dehydrogenase dysfunction
2. Wernicke encephalopathy classic triad (confusion, ataxia, ophthalmoplegia) is present in only 10-16% of cases - treat empirically
3. Thiamine must be given BEFORE dextrose in at-risk patients to prevent precipitating acute Wernicke encephalopathy
4. Wet beriberi causes high-output cardiac failure with peripheral vasodilation and tachycardia
5. Vitamin C depletes rapidly in sepsis but LOVIT trial showed harm with high-dose supplementation - NOT recommended
6. Vitamin D deficiency is common (40-80%) but VITdAL-ICU and VIOLET showed no mortality benefit with supplementation
7. Zinc and selenium deficiencies impair immune function but Cochrane reviews show no mortality benefit with supplementation
8. Refeeding syndrome occurs with carbohydrate reintroduction, causing hypophosphatemia, hypokalemia, hypomagnesemia, and thiamine depletion
9. NICE criteria identify high-risk patients: BMI <16, minimal intake >10 days, weight loss >15% in 3-6 months
10. Prevention protocol: Thiamine 200-300 mg IV BEFORE feeding, correct electrolytes, start at 10-20 kcal/kg/day, increase slowly

---

Definition and Epidemiology

Prevalence in Critical Illness

Nutritional deficiencies are remarkably common in ICU patients due to the catabolic stress response, inadequate nutritional provision, and increased micronutrient consumption during systemic inflammation. [1,2]

Australian/NZ Context: Aboriginal and Torres Strait Islander peoples have higher rates of nutritional deficiencies due to chronic disease burden (diabetes 3-4x, CKD 2-3x higher), food insecurity in remote communities, and limited access to fresh produce. [3,4]

Risk Factors for Nutritional Deficiency in ICU

Patient Factors:

• Chronic alcohol use disorder (thiamine, folate, magnesium, zinc)
• Malnutrition (BMI <18.5, weight loss >10% in 3-6 months)
• Chronic disease (diabetes, CKD, cirrhosis, cancer, IBD)
• Malabsorption (short bowel, pancreatic insufficiency, coeliac)
• Advanced age (reduced absorption, polypharmacy)
• Bariatric surgery (thiamine, B12, iron, calcium, vitamin D) [5]

Critical Illness Factors:

• Sepsis and SIRS (massive oxidative stress consumes antioxidants)
• Burns (selenium, zinc, vitamin C losses through wounds)
• Trauma and major surgery (increased metabolic demand)
• Prolonged mechanical ventilation (muscle wasting, delayed feeding)
• Acute kidney injury and CRRT (water-soluble vitamin losses) [6]

Iatrogenic Factors:

• Prolonged nil by mouth status
• Underfeeding (patients receive only 50-60% of prescribed calories)
• Diuretics (thiamine, magnesium, potassium)
• Broad-spectrum antibiotics (vitamin K)
• Proton pump inhibitors (magnesium, B12)
• Parenteral nutrition without adequate supplementation [7]

---

Thiamine Deficiency (Vitamin B1)

Biochemistry and Pathophysiology

Thiamine (vitamin B1) is a water-soluble vitamin that serves as an essential cofactor in the form of thiamine pyrophosphate (TPP) for three critical enzyme systems: [8,9]

1. Pyruvate Dehydrogenase Complex (PDH)

• Converts pyruvate to acetyl-CoA for entry into the Krebs cycle
• Dysfunction causes pyruvate to be shunted to lactate via lactate dehydrogenase
• Results in Type B lactic acidosis (adequate tissue oxygenation but metabolic dysfunction)

2. Alpha-Ketoglutarate Dehydrogenase

• Krebs cycle enzyme converting alpha-ketoglutarate to succinyl-CoA
• Impairment reduces ATP production via oxidative phosphorylation

3. Transketolase

• Pentose phosphate pathway enzyme
• Essential for NADPH production (antioxidant defense) and ribose synthesis (nucleic acids)

Body Stores and Depletion:

• Total body thiamine: 25-30 mg (half-life 10-20 days)
• Body stores can be depleted within 2-3 weeks of inadequate intake
• Demand increases 10-20 fold during sepsis and critical illness [10]
• CRRT removes thiamine (water-soluble, low molecular weight) [11]

Clinical Syndromes

Wernicke Encephalopathy

Pathology: Selective vulnerability of mammillary bodies, medial thalamus, periaqueductal gray matter, and superior vermis due to high metabolic demand and thiamine-dependent enzyme density.

Classic Triad (present in only 10-16% of cases): [12,13]

1. Encephalopathy: Confusion, disorientation, apathy, memory impairment
2. Oculomotor dysfunction: Nystagmus (horizontal > vertical), lateral rectus palsy (VI nerve), conjugate gaze palsy
3. Ataxia: Truncal > limb ataxia, wide-based gait

Non-Alcoholic Wernicke Encephalopathy - increasingly recognized in: [14]

• Hyperemesis gravidarum
• Post-bariatric surgery (gastric bypass, sleeve gastrectomy)
• Prolonged parenteral nutrition without thiamine
• Cancer patients with anorexia
• Dialysis patients
• Critically ill patients with prolonged nil oral status

Diagnosis:

• Clinical diagnosis - high index of suspicion required; do NOT wait for confirmatory testing
• Erythrocyte transketolase activity: Gold standard but rarely available acutely
• Plasma/whole blood thiamine: <70 nmol/L suggests deficiency
• MRI brain: Hyperintensity on T2/FLAIR in mammillary bodies, medial thalami, periaqueductal gray (sensitivity 53%, specificity 93%) [15]

Prognosis:

• Untreated mortality: 10-20%
• Progression to Korsakoff syndrome: 80% of untreated cases
• Korsakoff syndrome: Chronic irreversible amnesia, confabulation, apathy, personality change

Wet Beriberi (Cardiovascular)

Pathophysiology: Thiamine deficiency impairs myocardial oxidative metabolism, causing:

• Peripheral vasodilation (reduced vascular tone)
• High-output cardiac failure
• Biventricular failure in severe cases

Clinical Features: [16]

• Tachycardia, bounding pulses
• Warm peripheries despite low systemic vascular resistance
• Peripheral edema (bilateral, pitting)
• Elevated jugular venous pressure
• Cardiomegaly, S3 gallop
• Pulmonary edema, dyspnea
• High cardiac output (cardiac index >4 L/min/m2) with low SVR

ECG: Sinus tachycardia, low voltage QRS, T-wave inversions, prolonged QT

Echocardiography: Dilated ventricles, reduced ejection fraction (reversible with treatment)

Key Differential: Wet beriberi mimics septic shock (warm, vasodilated, hypotensive) but without infection source. Consider in persistent vasodilatory shock with high-output state.

Dry Beriberi (Neurological)

Clinical Features:

• Distal symmetric polyneuropathy (sensory > motor)
• Burning dysesthesias, paresthesias in feet
• Loss of ankle reflexes
• Weakness beginning distally
• Muscle wasting, foot drop in severe cases

Lactic Acidosis (Type B)

Mechanism: PDH dysfunction prevents pyruvate entry into Krebs cycle, shunting to lactate production despite adequate tissue oxygenation.

Clinical Clues to Thiamine Deficiency-Related Lactic Acidosis: [17,18]

• Persistent lactic acidosis (>4 mmol/L) despite adequate resuscitation
• Normal or elevated ScvO2 (>70%) - tissue oxygenation adequate
• Normal cardiac output and perfusion markers
• High-risk patient (alcohol use, malnutrition, prolonged critical illness)
• Failure to respond to conventional sepsis resuscitation
• Lactate clearance improves within 12-24 hours of thiamine administration

Management of Thiamine Deficiency

Prophylactic Supplementation (High-Risk Patients):

• Thiamine 100-300 mg IV daily for:
  • All patients with chronic alcohol use disorder
  • Severe malnutrition (BMI <18.5, minimal intake >7 days)
  • Prior to refeeding in at-risk patients
  • Patients receiving parenteral nutrition
  • Bariatric surgery patients [19]

CRITICAL: Give thiamine BEFORE dextrose-containing fluids in at-risk patients to prevent precipitating acute Wernicke encephalopathy. [20]

Therapeutic Dosing - Wernicke Encephalopathy: According to EFNS guidelines and Royal College of Physicians (UK): [12,13]

• Thiamine 500 mg IV TID for 3-5 days
• Then 250 mg IV/IM daily for 3-5 days
• Then 100 mg oral TID until risk factors resolved
• Administer with concurrent glucose, magnesium (magnesium is TPP cofactor)

Therapeutic Dosing - Lactic Acidosis/Wet Beriberi:

• Thiamine 200-500 mg IV q8h
• Continue until lactate normalized and clinical improvement
• Response typically seen within 12-24 hours [17]

Australian TGA-Approved Formulations:

• Thiamine hydrochloride 100 mg tablets (oral)
• Thiamine 100 mg/mL injection (IM/slow IV) - PBS listed for Wernicke, beriberi

---

Vitamin C Deficiency (Ascorbic Acid)

Biochemistry and Functions

Vitamin C is a water-soluble antioxidant and enzymatic cofactor essential for: [21]

1. Antioxidant Defense: Scavenges reactive oxygen species (ROS), regenerates vitamin E
2. Collagen Synthesis: Cofactor for prolyl and lysyl hydroxylases (wound healing)
3. Catecholamine Synthesis: Cofactor for dopamine beta-hydroxylase (norepinephrine production)
4. Immune Function: Neutrophil chemotaxis, phagocytosis, lymphocyte proliferation
5. Endothelial Integrity: Preserves endothelial barrier function, reduces capillary leak

Depletion in Critical Illness

Vitamin C is rapidly depleted in sepsis and critical illness: [22,23]

• Plasma levels drop to <11 micromol/L (deficient) within 24-48 hours of ICU admission in sepsis
• Hypovitaminosis C (<23 micromol/L) in 38-60% of ICU patients
• Mechanism: Massive oxidative stress consumes vitamin C as antioxidant; enhanced renal clearance; redistribution into activated leukocytes

Clinical Features of Scurvy

Overt scurvy is uncommon in modern ICUs but may occur with prolonged critical illness: [24]

• Petechiae, ecchymoses (capillary fragility)
• Perifollicular hemorrhages (pathognomonic)
• Gingival bleeding, swelling
• Poor wound healing
• Corkscrew hairs
• Joint pain and swelling (hemarthrosis)
• Impaired immunity, increased infection risk

Evidence for Vitamin C in Sepsis - Major Trials

CITRIS-ALI Trial (2019) - PMID: 30625275 [25]

VITAMINS Trial (2020) - PMID: 31577396 [26]

LOVIT Trial (2022) - PMID: 35939567 [27]

ACTS Trial (2021) - PMID: 32920232 [28]

Current Recommendations

Surviving Sepsis Campaign 2021: [29]

• Routine high-dose vitamin C (>3 g/day) NOT recommended in sepsis
• Standard supplementation (100-200 mg/day) reasonable to prevent deficiency

Clinical Practice:

• Ensure adequate vitamin C in enteral/parenteral nutrition (100-200 mg/day)
• Do NOT use "metabolic resuscitation cocktails" with high-dose vitamin C
• Consider standard replacement if documented deficiency or scurvy

---

Vitamin D Deficiency

Epidemiology in Critical Illness

Vitamin D deficiency is remarkably prevalent in ICU patients: [30,31]

• Deficiency (<50 nmol/L or <20 ng/mL): 40-80% of ICU patients
• Severe deficiency (<30 nmol/L or <12 ng/mL): 17-26%
• Associated with increased mortality, longer ICU stay, higher infection rates

Mechanisms of Deficiency in Critical Illness:

• Reduced synthesis (no sun exposure in ICU)
• Consumption during acute phase response
• Reduced hepatic 25-hydroxylation in liver dysfunction
• Enhanced degradation and urinary losses
• Vitamin D-binding protein lost in proteinuria, burns, capillary leak [32]

Immunomodulatory Effects

Vitamin D has pleiotropic effects beyond bone metabolism: [33,34]

• Upregulates antimicrobial peptides (cathelicidin, defensins)
• Modulates innate immunity (macrophage differentiation)
• Regulates adaptive immunity (T-cell function)
• Anti-inflammatory (downregulates NF-kappaB, reduces cytokine production)
• Enhances epithelial barrier integrity

Major Trials

VITdAL-ICU Trial (2014) - PMID: 25268295 [35]

VIOLET Trial (2019) - PMID: 31940698 [36]

Current Recommendations

• Routine high-dose vitamin D supplementation NOT recommended in critical illness
• Standard replacement (1,000-2,000 IU daily) reasonable for documented deficiency
• Subgroup with severe deficiency (<30 nmol/L) may benefit - further trials needed
• Check 25(OH)D level in prolonged ICU stay, chronic disease, immunocompromised [37]

---

Zinc and Selenium Deficiency

Zinc

Functions in Critical Illness: [38]

• Cofactor for >300 zinc-dependent enzymes
• Immune function (T-cell maturation, NK cell activity, macrophage function)
• Wound healing (collagen synthesis, epithelialization)
• Protein synthesis and tissue repair
• Antioxidant defense (superoxide dismutase)

Deficiency in ICU:

• Hypozincemia (plasma <10.7 micromol/L) in 30-40% of ICU patients
• Redistribution during acute phase response (hepatic sequestration lowers plasma levels)
• Enhanced losses (burns, diarrhea, fistulas, CRRT)
• Impaired absorption (GI dysfunction, proton pump inhibitors) [39]

Clinical Consequences:

• Immune dysfunction, increased infection risk
• Delayed wound healing
• Dermatitis (acrodermatitis enteropathica pattern)
• Alopecia, taste abnormalities
• Associated with higher APACHE scores and mortality [40]

Evidence for Supplementation:

• Limited evidence for routine supplementation
• Consider supplementation (22-45 mg elemental zinc daily) in:
  • Documented deficiency
  • Burns, wound healing problems
  • Severe malnutrition
• Toxicity: Chronic high-dose (>40 mg/day) interferes with copper absorption, causing copper deficiency anemia and myeloneuropathy [41]

Selenium

Functions in Critical Illness: [42]

• Incorporated into selenoproteins (25 types in humans)
• Glutathione peroxidase: Reduces hydrogen peroxide and lipid peroxides (antioxidant)
• Thioredoxin reductase: Maintains cellular redox state
• Selenoprotein P: Selenium transport and antioxidant function
• Deiodinases: Thyroid hormone activation (T4 to T3)

Deficiency in ICU:

• Plasma selenium <70 microg/L in 40-60% of septic patients
• Mechanisms: Redistribution, oxidative consumption, renal/GI losses (CRRT)
• Associated with prolonged ventilation, increased infection risk [43]

Evidence for Supplementation:

Cochrane Review (2015) - PMID: 25927840: [44]

• 16 RCTs, n=2,084 critically ill patients
• Selenium supplementation: NO mortality benefit (RR 0.99, 95% CI 0.86-1.14)
• Possible benefit in sepsis subgroup but underpowered

Current Practice:

• Routine high-dose selenium supplementation NOT recommended
• Supplementation (60-100 mcg/day) in parenteral nutrition
• Consider higher doses (500 mcg/day) only in documented severe deficiency

Toxicity (Selenosis):

• Chronic intake >400 mcg/day
• Symptoms: Garlic breath, metallic taste, hair/nail loss, nausea, neurological symptoms [45]

---

Refeeding Syndrome

Definition and Pathophysiology

Refeeding syndrome is a potentially life-threatening constellation of metabolic disturbances that occurs when nutrition is reintroduced after a period of prolonged fasting or severe malnutrition. [46,47]

Key Metabolic Derangements:

1. Hypophosphatemia (hallmark)
2. Hypokalemia
3. Hypomagnesemia
4. Thiamine deficiency
5. Fluid and sodium retention

Pathophysiology:

During starvation, the body adapts to using fat and ketones for energy:

• Reduced insulin secretion
• Gluconeogenesis from protein catabolism
• Intracellular electrolyte stores depleted but serum levels may remain normal
• Body composition shifts (loss of lean mass, intracellular water)

Upon refeeding with carbohydrate:

• Insulin secretion surges
• Glucose enters cells, driving anabolic processes
• Phosphate, potassium, magnesium shift intracellularly for:
  • ATP synthesis (phosphate)
  • Glycogen deposition (potassium)
  • Protein synthesis (all three)
• Thiamine rapidly consumed for carbohydrate metabolism
• Insulin causes renal sodium and water retention (edema)

NICE Criteria for Refeeding Risk [48]

One or More of the Following:

• BMI <16 kg/m2
• Unintentional weight loss >15% within last 3-6 months
• Little or no nutritional intake for >10 days
• Low levels of potassium, phosphate, or magnesium before feeding

OR Two or More of the Following:

• BMI <18.5 kg/m2
• Unintentional weight loss >10% within last 3-6 months
• Little or no nutritional intake for >5 days
• History of: alcohol misuse, drug use (including insulin, chemotherapy, antacids, diuretics)

Clinical Consequences of Refeeding Syndrome

Severe Hypophosphatemia (<0.32 mmol/L): [49]

• Respiratory: Diaphragmatic weakness, respiratory failure, prolonged ventilation (phosphate required for 2,3-DPG and ATP)
• Cardiac: Arrhythmias, heart failure, hypotension
• Neurological: Encephalopathy, seizures, paresthesias
• Hematological: Hemolysis, impaired WBC function
• Musculoskeletal: Rhabdomyolysis, proximal myopathy

Hypokalemia:

• Cardiac arrhythmias (VT/VF, torsades)
• Muscle weakness, paralysis
• Respiratory failure

Hypomagnesemia:

• Cardiac arrhythmias (atrial fibrillation, torsades)
• Tetany, seizures
• Refractory hypokalemia and hypocalcemia

Thiamine Deficiency:

• Wernicke encephalopathy
• Lactic acidosis
• Wet beriberi (high-output cardiac failure)

Fluid Overload:

• Peripheral edema
• Pulmonary edema
• Heart failure

Prevention Protocol (ASPEN/ESPEN/NICE Guidelines) [46,47,48]

Step 1: Identify High-Risk Patients

Apply NICE criteria at ICU admission and before initiating nutrition

Step 2: Pre-Feeding Interventions

Thiamine Supplementation (CRITICAL):

• Thiamine 200-300 mg IV daily for 3-5 days BEFORE and during nutrition initiation
• Prevents Wernicke encephalopathy and lactic acidosis precipitated by carbohydrate load

Correct Electrolyte Abnormalities BEFORE Feeding:

• Phosphate >0.65 mmol/L (>2.0 mg/dL)
• Magnesium >0.5 mmol/L (>1.2 mg/dL)
• Potassium >3.5 mmol/L
• Administer IV supplementation if deficient

Step 3: Nutrition Initiation ("Start Low, Go Slow")

Energy:

• Start at 10-20 kcal/kg/day (or ≤50% of estimated requirements)
• Approximately 10-15 kcal/kg/day for extreme risk (BMI <14, no intake >15 days)
• Increase by 20% every 2-3 days
• Reach target (25-30 kcal/kg/day) by days 5-7

Protein:

• Start at 1.2-1.5 g/kg/day
• Protein does NOT trigger refeeding syndrome and should NOT be restricted

Fluids:

• Restrict fluids initially (20-30 mL/kg/day)
• Avoid sodium overload
• Monitor for fluid retention

Step 4: Monitoring

Daily for 5-7 Days After Starting Nutrition:

• Phosphate, magnesium, potassium, sodium
• Glucose (insulin sensitivity changes with refeeding)
• Fluid balance (daily weights, input/output)
• Clinical assessment (edema, respiratory status, cardiac rhythm)

If Hypophosphatemia Develops (PO4 <0.65 mmol/L):

• REDUCE caloric intake to 20 kcal/hour for 48 hours
• Aggressively replace phosphate (0.16-0.64 mmol/kg IV over 6-12 hours)
• Do NOT resume full feeding until phosphate stable
• This is the REFEED Trial approach (PMID: 26653063) [50]

REFEED Trial (2015) - PMID: 26653063 [50]

---

Assessment of Nutritional Status in ICU

Challenges in Critical Illness

Traditional nutritional assessment tools have limitations in ICU: [51]

• Weight changes reflect fluid shifts, not lean mass
• Albumin/prealbumin are negative acute phase reactants (not nutritional markers)
• Dietary history unreliable in emergent admissions
• Body composition measurement impractical

Nutritional Assessment Tools

Subjective Global Assessment (SGA)

Components:

• Weight change history
• Dietary intake changes
• GI symptoms affecting intake
• Functional capacity
• Physical examination (muscle/fat wasting, edema)

Classification: A (well-nourished), B (moderate malnutrition), C (severe malnutrition)

Limitation: Requires detailed history, subjective, not validated specifically for ICU

NUTRIC Score (NUtrition Risk In the Critically ill) [52]

Variables (scored 0-10):

• Age
• APACHE II score
• SOFA score
• Number of comorbidities
• Days from hospital to ICU admission
• IL-6 level (optional, often omitted)

Interpretation:

• Score ≥5 (or ≥6 with IL-6): High nutritional risk - benefit from aggressive nutritional therapy
• Score <5: Lower nutritional risk

Advantage: Validated in ICU, uses readily available data

Nutritional Risk Screening 2002 (NRS-2002)

Components:

• Nutritional score (0-3): BMI, weight loss, food intake
• Disease severity score (0-3): Based on diagnosis category
• Age adjustment: +1 if ≥70 years

Interpretation: Total ≥3 = at nutritional risk

mNUTRIC Score (Modified without IL-6)

Most commonly used in practice due to IL-6 availability issues. Cutoff ≥5 indicates high risk.

Laboratory Markers

NOT Indicators of Nutritional Status in Acute Illness:

• Albumin: Negative acute phase reactant, reflects inflammation not nutrition
• Prealbumin (transthyretin): Negative acute phase reactant, half-life 2-3 days, affected by inflammation
• Transferrin: Affected by iron status and inflammation

Useful for Specific Deficiencies:

• Thiamine: Erythrocyte transketolase, plasma/whole blood thiamine
• Vitamin D: 25-hydroxyvitamin D
• Vitamin B12: Serum B12, methylmalonic acid
• Folate: Serum folate, RBC folate
• Iron: Ferritin, transferrin saturation (interpret with CRP - ferritin is acute phase reactant)
• Trace elements: Zinc, selenium, copper (availability varies)

Practical Approach to Nutritional Assessment in ICU

1. Identify malnutrition risk at admission: NUTRIC score, NICE refeeding criteria
2. Assess for specific deficiency risk factors: Alcohol use, malabsorption, prolonged fasting, chronic disease
3. Clinical examination: Muscle wasting (temporalis, deltoid, quadriceps), subcutaneous fat loss, edema
4. Targeted laboratory testing: Based on risk factors (thiamine in alcohol use, vitamin D in prolonged ICU, etc.)
5. Monitor response to nutritional therapy: Weight trends, nitrogen balance (if available), wound healing, functional status

---

Micronutrient Supplementation Protocols

Routine ICU Supplementation

Enteral Nutrition:

• Most commercial EN formulas provide RDA levels of micronutrients
• Patients receiving ≥1,500 kcal/day from EN generally meet requirements
• High-risk patients (burns, wounds, dialysis) may need additional supplementation

Parenteral Nutrition: Standard TPN should include: [53]

• Water-soluble vitamins (B-complex, vitamin C)
• Fat-soluble vitamins (A, D, E, K)
• Trace elements (zinc, copper, selenium, manganese, chromium, molybdenum)

Daily Trace Element Requirements in TPN:

Specific Supplementation Protocols

Refeeding Syndrome Prevention:

• Thiamine 200-300 mg IV daily x 3-5 days
• Multivitamin daily
• Phosphate, magnesium, potassium replacement PRN

Burns (>20% TBSA):

• Increased requirements: Vitamin C 500-1000 mg/day, Zinc 22-45 mg/day, Selenium 200-500 mcg/day
• Copper 2-4 mg/day for wound healing
• Monitor levels weekly [54]

Renal Replacement Therapy (CRRT):

• Water-soluble vitamins lost in effluent
• Supplement thiamine 100 mg/day, vitamin C 100-200 mg/day
• Selenium and zinc losses - monitor and replace
• Folate 1 mg/day [55]

Chronic Alcohol Use:

• Thiamine 200-300 mg IV x 3-5 days, then 100 mg oral daily
• Folate 5 mg daily
• Magnesium replacement (often depleted)
• Multivitamin with zinc

Bariatric Surgery Patients:

• Thiamine (high risk for deficiency)
• Vitamin B12 1000 mcg IM monthly (if gastric bypass)
• Iron, calcium, vitamin D supplementation
• Monitor levels regularly [56]

Monitoring Strategy

At ICU Admission (High-Risk Patients):

• Thiamine level (if available) or empiric treatment
• Phosphate, magnesium, potassium (baseline before feeding)
• Vitamin D in prolonged ICU expected
• Full blood count (macrocytosis suggests B12/folate)

During ICU Stay:

• Electrolytes (PO4, Mg, K): Daily for 5-7 days after starting nutrition
• Vitamin D: q4-6 weeks if prolonged ICU
• Trace elements (Zn, Se, Cu): q2-4 weeks if prolonged TPN or high losses

Before ICU Discharge:

• Address ongoing nutritional needs for ward/home
• Arrange follow-up of deficiencies
• Liaise with dietitian for long-term planning

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples [3,4,57]

Higher Prevalence of Nutritional Deficiencies:

• Vitamin D: 30-60% deficiency despite sun exposure (skin pigmentation, indoor occupations, cultural clothing)
• Iron: Higher prevalence due to chronic disease, hookworm in tropical regions
• Zinc: Common with diabetes, CKD (higher prevalence in Aboriginal populations)
• Folate: Lower intake in remote communities (limited fresh vegetables)

Contributing Factors:

• Chronic disease burden: Diabetes (3-4x), CKD (2-3x), cardiovascular disease (2x) higher prevalence
• Food insecurity: Remote communities have limited access to affordable fresh produce
• "Food deserts": High cost of nutritious food, reliance on processed/canned foods
• Traditional bush foods: Rich in micronutrients but reduced consumption

Cultural Considerations:

• Involve Aboriginal Health Workers (AHW) and Aboriginal Hospital Liaison Officers (AHLO)
• Family-centered decision-making: Include Elders and extended family
• Culturally appropriate communication: Yarning (conversational storytelling), visual aids, plain language
• Address barriers to supplement adherence: Literacy, cost, medication complexity, distrust of healthcare

Remote ICU/Retrieval Considerations:

• RFDS retrievals: Empiric thiamine before dextrose in suspected malnutrition
• Telehealth support for remote high-dependency units
• Limited on-site micronutrient testing - use clinical judgment
• Coordinate with Aboriginal Community Controlled Health Organisations (ACCHOs) for follow-up

Maori Health (New Zealand) [58]

Higher Prevalence:

• Vitamin D deficiency: 30-50% (higher latitude, skin pigmentation)
• Iron deficiency: Higher in Maori women and children
• Chronic disease: Diabetes 1.5-2x, CKD higher prevalence

Cultural Considerations:

• Whanau (family)-centered care: Include extended family in nutrition planning
• Tikanga (cultural practices): Respect protocols, involve kaumatua (elders)
• Kaupapa Maori services: Utilize Maori health providers for culturally safe care
• Te Tiriti o Waitangi: Equitable access to testing and treatment

---

CICM Exam Assessment Content

SAQ Practice Question 1: Thiamine Deficiency and Lactic Acidosis (20 marks)

Question: A 52-year-old man with chronic alcohol use disorder is admitted to ICU with community-acquired pneumonia and septic shock. He is intubated, mechanically ventilated, and requiring norepinephrine 0.25 mcg/kg/min. Initial lactate is 7.8 mmol/L. After 6 hours of appropriate resuscitation with crystalloid, antibiotics, and source control, the following parameters are noted:

• MAP 70 mmHg (on norepinephrine 0.15 mcg/kg/min)
• ScvO2 72%
• CVP 10 mmHg
• Cardiac output 7.2 L/min (cardiac index 4.1 L/min/m2)
• Lactate 7.2 mmol/L (unchanged)
• pH 7.28, HCO3 16 mmol/L, BE -10

(a) What is the most likely explanation for the persistent lactic acidosis despite adequate resuscitation, and explain the underlying pathophysiology? (6 marks)

(b) Describe TWO other clinical syndromes caused by this micronutrient deficiency relevant to critical care. (4 marks)

(c) Outline your management plan, including dosing and monitoring. (6 marks)

(d) Why must this intervention be given BEFORE dextrose-containing fluids in at-risk patients? (4 marks)

---

Model Answer:

(a) Most Likely Explanation - Thiamine Deficiency (6 marks):

The most likely explanation is Type B lactic acidosis secondary to thiamine deficiency. (1 mark)

Evidence supporting this diagnosis:

• Persistent lactate (7.2 mmol/L) despite adequate resuscitation (MAP 70, ScvO2 72%, CVP 10) (1 mark)
• High cardiac output (CI 4.1 L/min/m2) - tissue perfusion is adequate (Type A lactic acidosis excluded) (1 mark)
• High-risk patient: Chronic alcohol use disorder is the commonest cause of thiamine deficiency in developed countries (1 mark)

Pathophysiology (2 marks): Thiamine (vitamin B1) is an essential cofactor for the pyruvate dehydrogenase (PDH) complex, which converts pyruvate to acetyl-CoA for entry into the Krebs cycle.

In thiamine deficiency, PDH cannot function. Pyruvate cannot enter aerobic metabolism and is shunted via lactate dehydrogenase to lactate, causing Type B lactic acidosis - lactic acidosis in the presence of adequate tissue oxygenation.

Thiamine is also a cofactor for alpha-ketoglutarate dehydrogenase (Krebs cycle) and transketolase (pentose phosphate pathway), further impairing cellular ATP production.

(b) Two Other Clinical Syndromes (4 marks - 2 marks each):

1. Wernicke Encephalopathy:

• Acute neurological syndrome due to thiamine depletion in metabolically active brain regions (mammillary bodies, medial thalamus, periaqueductal gray)
• Classic triad (present in only 10-16%): confusion/encephalopathy, ataxia, ophthalmoplegia (nystagmus, lateral rectus palsy)
• Can progress to irreversible Korsakoff syndrome (chronic amnesia, confabulation) if untreated

2. Wet Beriberi (Cardiovascular Beriberi):

• High-output cardiac failure due to impaired myocardial oxidative metabolism
• Clinical features: Tachycardia, warm peripheries, peripheral edema, elevated JVP, cardiomegaly, low SVR
• Mimics septic shock (warm, vasodilated, hypotensive) - consider in refractory vasodilatory shock
• Reversible with thiamine administration

(c) Management Plan (6 marks):

Immediate Treatment (2 marks):

• Thiamine 200-500 mg IV immediately (before any dextrose-containing fluids)
• Administer as slow IV infusion (risk of anaphylactoid reaction rare but possible)

Ongoing Thiamine Dosing (2 marks):

• Thiamine 200-500 mg IV TID for 3-5 days (high-dose for suspected Wernicke or severe deficiency)
• Then 250 mg IV/IM daily for 3-5 days
• Transition to thiamine 100 mg oral TID when tolerating enteral nutrition
• Continue until risk factors resolved

Monitoring and Adjuncts (2 marks):

• Repeat lactate q2-4 hours - expect decrease within 12-24 hours if thiamine-deficient
• Monitor clinical response (mental status, ataxia, eye movements if Wernicke suspected)
• Correct concurrent deficiencies:
  • Magnesium (often deficient in alcoholics; magnesium is TPP cofactor)
  • Potassium, phosphate (risk of refeeding syndrome)
  • Multivitamin, folate supplementation
• Continue sepsis management (antibiotics, source control, vasopressors)

(d) Rationale for Thiamine Before Dextrose (4 marks):

Mechanism of Harm (2 marks): Administering dextrose (glucose load) in a thiamine-deficient patient creates sudden increased demand for thiamine. Glucose metabolism requires thiamine as a cofactor for PDH and the Krebs cycle. In a patient with already marginal or depleted thiamine stores, this glucose load rapidly exhausts any remaining thiamine.

Clinical Consequence (2 marks): This can precipitate acute Wernicke encephalopathy. The mammillary bodies and medial thalamus are particularly vulnerable due to high metabolic activity and thiamine-dependent enzyme density. Without thiamine, glucose cannot be metabolized aerobically, and these brain regions suffer acute metabolic failure.

If untreated, Wernicke encephalopathy can progress to irreversible Korsakoff syndrome (80% of cases) or death (10-20% mortality). Thiamine is extremely safe even in high doses, so empiric treatment in at-risk patients is mandatory.

---

SAQ Practice Question 2: Refeeding Syndrome (20 marks)

Question: A 38-year-old woman with anorexia nervosa is admitted to ICU following cardiac arrest (VF) in the emergency department. ROSC was achieved after 8 minutes. She weighs 42 kg (BMI 15.2 kg/m2) and her mother reports she has been eating "almost nothing" for the past 3 weeks.

Initial investigations show:

• K+ 2.8 mmol/L
• PO4 0.42 mmol/L
• Mg2+ 0.38 mmol/L
• pH 7.52, HCO3 30 mmol/L (metabolic alkalosis)
• QTc 520 ms

(a) Identify the risk factors for refeeding syndrome in this patient according to NICE criteria. (4 marks)

(b) Explain the pathophysiology of refeeding syndrome, including the mechanism of hypophosphatemia. (6 marks)

(c) Outline your prevention strategy before initiating nutrition, including specific interventions and dosing. (6 marks)

(d) Describe your nutrition initiation and monitoring protocol. (4 marks)

---

Model Answer:

(a) Risk Factors for Refeeding Syndrome - NICE Criteria (4 marks):

This patient has extremely high risk for refeeding syndrome.

NICE "One or More" Criteria Present (1 mark each, max 2):

1. BMI <16 kg/m2: BMI 15.2 kg/m2 (below threshold)
2. Little or no nutritional intake for >10 days: 3 weeks of minimal intake (21 days)

NICE "Two or More" Criteria Present (1 mark each, max 2):

1. BMI <18.5 kg/m2 (BMI 15.2)
2. History of alcohol misuse, drug use, or psychiatric illness - anorexia nervosa
3. Pre-existing electrolyte abnormalities: K+ 2.8, PO4 0.42, Mg2+ 0.38 mmol/L

(b) Pathophysiology of Refeeding Syndrome (6 marks):

Starvation Adaptation (2 marks): During prolonged fasting, the body shifts from carbohydrate to fat oxidation for energy. Insulin secretion decreases, and gluconeogenesis from protein provides glucose for obligate glucose-dependent tissues (brain, RBCs). Intracellular electrolytes (phosphate, potassium, magnesium) become depleted as they are consumed for basal cellular processes, but serum levels may remain near-normal because there is reduced anabolic uptake.

Refeeding Response (2 marks): When carbohydrate is reintroduced:

• Insulin secretion surges in response to glucose
• Glucose and electrolytes are driven into cells for anabolic processes
• Glycogen synthesis requires potassium and water
• Protein synthesis requires phosphate (for ATP) and magnesium
• Phosphate is consumed for ATP production, 2,3-DPG synthesis, and phospholipid membranes

Mechanism of Hypophosphatemia (2 marks): Hypophosphatemia is the hallmark of refeeding syndrome because:

1. Phosphate shifts from extracellular to intracellular compartment driven by insulin
2. Phosphate is incorporated into ATP for energy-requiring anabolic processes
3. Phosphate is used for 2,3-DPG production (increases in response to refeeding)
4. Pre-existing phosphate depletion (from starvation) is unmasked

Severe hypophosphatemia (<0.32 mmol/L) causes ATP depletion in all cells, leading to respiratory failure (diaphragm weakness), cardiac dysfunction, neurological impairment, and hemolysis.

(c) Prevention Strategy Before Initiating Nutrition (6 marks):

1. Thiamine Supplementation (2 marks):

• Thiamine 200-300 mg IV daily BEFORE and during nutrition initiation (for at least 3-5 days)
• Prevents Wernicke encephalopathy and lactic acidosis precipitated by carbohydrate metabolism
• Give before any dextrose-containing fluids

2. Correct Electrolyte Abnormalities BEFORE Feeding (2 marks):

• Correct magnesium FIRST (required for potassium and phosphate correction)
• Central line access for concentrated potassium infusion
• Continuous cardiac monitoring given prolonged QTc (520 ms)

3. Multivitamin and Trace Elements (1 mark):

• Multivitamin preparation daily (B-complex, fat-soluble vitamins)
• Zinc supplementation (often deficient)
• Consider vitamin D if prolonged ICU stay anticipated

4. Avoid Fluid Overload (1 mark):

• Restrict fluids initially (20-30 mL/kg/day)
• Avoid sodium overload (insulin causes sodium and water retention)
• Monitor for peripheral and pulmonary edema

(d) Nutrition Initiation and Monitoring Protocol (4 marks):

Nutrition Initiation - "Start Low, Go Slow" (2 marks):

Energy:

• Calculate estimated requirements: 25-30 kcal/kg/day = 1,050-1,260 kcal/day for 42 kg
• Start at 10 kcal/kg/day (420 kcal/day) given extreme risk (BMI <16, >15 days fasting)
• Increase by 20% every 2-3 days
• Reach target by days 5-7

Protein:

• Start at 1.2-1.5 g/kg/day (50-63 g/day)
• Protein does NOT trigger refeeding and should NOT be restricted

Route:

• Enteral nutrition preferred if gut functional
• Start with continuous infusion (reduces insulin spikes)

Monitoring Protocol (2 marks):

If Hypophosphatemia Develops (PO4 <0.65 mmol/L):

• REDUCE caloric intake to 20 kcal/hour for 48 hours
• Aggressively replace phosphate IV
• Resume feeding only when phosphate stable

---

Viva Scenario 1: Nutritional Deficiencies in Sepsis (20 marks)

Scenario: You are the ICU registrar. A 58-year-old man with chronic alcohol use disorder is in ICU Day 3 with severe community-acquired pneumonia and septic shock. He required intubation and has been on norepinephrine (currently 0.08 mcg/kg/min, weaning). The nursing staff ask about starting enteral nutrition today.

---

Examiner: What nutritional considerations are relevant for this patient?

Candidate: This patient has multiple risk factors for nutritional deficiencies that I need to consider before starting enteral nutrition:

Patient Risk Factors:

1. Chronic alcohol use disorder - high risk for thiamine, folate, magnesium, and zinc deficiency
2. Critical illness/sepsis - increased metabolic demand, oxidative stress depleting antioxidants (vitamin C, selenium)
3. Prolonged reduced oral intake - likely NPO for several days before and during ICU admission
4. Septic shock - catabolic state with muscle wasting, redistributive losses

My Approach:

1. Assess for refeeding syndrome risk using NICE criteria
2. Ensure thiamine supplementation before starting nutrition
3. Check and correct electrolyte abnormalities (phosphate, magnesium, potassium)
4. Start enteral nutrition at appropriate rate based on risk assessment

---

Examiner: His lactate was 8.2 mmol/L on admission and is still 6.5 mmol/L despite apparent resolution of septic shock. How do you interpret this?

Candidate: A persistent lactic acidosis despite resolution of shock (weaning vasopressors, presumably adequate perfusion) raises concern for Type B lactic acidosis rather than Type A (tissue hypoperfusion).

Differential for Type B Lactic Acidosis in This Patient:

1. Thiamine deficiency - Most likely given chronic alcohol use. Thiamine is a cofactor for pyruvate dehydrogenase; deficiency shunts pyruvate to lactate.
2. Metformin toxicity - unlikely unless on metformin
3. Liver dysfunction - impaired lactate clearance
4. Mitochondrial dysfunction from severe sepsis

My Immediate Action:

• Administer thiamine 200-500 mg IV immediately
• Repeat lactate in 4-6 hours - expect decrease within 12-24 hours if thiamine-responsive
• Check thiamine level if available (though do not delay treatment)
• Ensure magnesium is corrected (magnesium is a cofactor for thiamine pyrophosphate)

---

Examiner: You give thiamine and start enteral nutrition. On Day 4, phosphate drops from 0.85 to 0.52 mmol/L. What is happening?

Candidate: This is refeeding syndrome - the phosphate drop after starting nutrition is the hallmark sign.

Mechanism: The introduction of carbohydrate causes insulin secretion, which drives phosphate intracellularly for ATP synthesis, glycogen deposition, and anabolic processes. In a patient with depleted phosphate stores from malnutrition, this causes rapid hypophosphatemia.

My Management:

1. Reduce caloric intake to 20 kcal/hour for 48 hours (REFEED Trial approach)
2. Replace phosphate aggressively - potassium or sodium phosphate 0.16-0.32 mmol/kg IV over 6 hours
3. Check magnesium and potassium - often fall concurrently; correct all three
4. Continue thiamine 200-300 mg IV daily
5. Monitor electrolytes q12h until stable
6. Resume feeding slowly once phosphate >0.65 mmol/L and stable - increase by 20% increments every 2-3 days

---

Examiner: What evidence exists for vitamin C supplementation in sepsis? The patient's family read online that vitamin C cures sepsis.

Candidate: This is a common question from families given media coverage. The evidence for vitamin C in sepsis has evolved significantly:

Key Trials:

CITRIS-ALI (2019): Vitamin C 50 mg/kg q6h in sepsis-induced ARDS

• Primary outcome: No improvement in SOFA scores
• Secondary outcome: Lower 28-day mortality (29.8% vs 46.3%, p=0.03)
• Interpretation: Suggestive but underpowered for mortality

VITAMINS Trial (2020) - Australian/NZ trial:

• Vitamin C + thiamine + hydrocortisone vs hydrocortisone alone in septic shock
• Primary outcome: No difference in time alive and free of vasopressors
• Interpretation: Metabolic resuscitation cocktail provides no benefit

LOVIT Trial (2022) - Largest trial:

• Vitamin C 50 mg/kg q6h vs placebo in septic shock
• Primary outcome: HIGHER death or persistent organ dysfunction with vitamin C (50.1% vs 43.6%)
• Interpretation: High-dose vitamin C may be HARMFUL

Current Recommendation (Surviving Sepsis Campaign 2021):

• Routine high-dose vitamin C (>3 g/day) is NOT recommended in sepsis
• Standard supplementation (100-200 mg/day) to prevent deficiency is reasonable

My Response to the Family: I would explain that while vitamin C was promising in early studies, the largest and most rigorous trial showed potential harm. We ensure adequate vitamin C through nutrition but do not use high doses. I would validate their interest in his care while providing evidence-based information.

---

Examiner: If this patient were an Aboriginal man from a remote community, what additional considerations would you have?

Candidate: Aboriginal and Torres Strait Islander peoples have specific nutritional considerations:

Higher Prevalence of Deficiencies:

• Vitamin D deficiency (30-60%) despite sun exposure - skin pigmentation reduces synthesis
• Iron deficiency - chronic disease burden, hookworm in tropical regions
• Zinc deficiency - common with diabetes and CKD (higher prevalence in Aboriginal populations)
• Folate - limited access to fresh vegetables in remote communities

Contributing Factors:

• Chronic disease: Diabetes 3-4x higher, CKD 2-3x higher, cardiovascular disease 2x higher
• Food insecurity: Remote communities have limited affordable fresh produce
• Traditional bush foods are nutrient-rich but consumption has decreased

Cultural Considerations:

1. Involve Aboriginal Health Worker (AHW) and Aboriginal Hospital Liaison Officer (AHLO) early
2. Family-centered decision-making: Include Elders and extended family in nutrition discussions
3. Culturally appropriate communication: Use yarning, visual aids, plain language
4. Address barriers to supplement adherence: Literacy, cost, medication complexity

Specific Actions:

• Screen for and treat nutritional deficiencies empirically given high prevalence
• Coordinate with remote health service for post-discharge follow-up
• Engage ACCHO (Aboriginal Community Controlled Health Organisation) for ongoing care
• Consider telehealth support for remote follow-up

---

Viva Scenario 2: Vitamin D and Evidence Interpretation (20 marks)

Scenario: A colleague suggests you should prescribe high-dose vitamin D (500,000 IU loading dose) to all ICU patients because "vitamin D deficiency causes increased mortality."

---

Examiner: What is the prevalence of vitamin D deficiency in ICU and what are its associations?

Candidate: Vitamin D deficiency is highly prevalent in critically ill patients:

Prevalence:

• Deficiency (<50 nmol/L or <20 ng/mL): 40-80% of ICU patients
• Severe deficiency (<30 nmol/L or <12 ng/mL): 17-26%

Associations (Observational Data):

• Increased mortality
• Longer ICU and hospital length of stay
• Higher infection rates
• Increased need for mechanical ventilation
• Acute kidney injury

Mechanisms of Association: Vitamin D has immunomodulatory effects:

• Upregulates antimicrobial peptides (cathelicidin, defensins)
• Modulates innate and adaptive immunity
• Anti-inflammatory effects (downregulates NF-kappaB)
• Maintains epithelial barrier integrity

However, association does not prove causation - vitamin D may be a marker of illness severity rather than a cause of poor outcomes.

---

Examiner: What does the trial evidence show for vitamin D supplementation in critical illness?

Candidate: Two major trials have addressed this question:

VITdAL-ICU Trial (2014) - Austria:

• 475 critically ill patients with vitamin D deficiency (<50 nmol/L)
• Intervention: Vitamin D3 540,000 IU loading, then 90,000 IU monthly vs placebo
• Primary outcome: Hospital length of stay - NO DIFFERENCE
• Mortality: No difference overall
• Subgroup analysis: Reduced mortality in severe deficiency (<30 nmol/L) - 28.6% vs 46.1%, p=0.04
• Interpretation: No benefit in unselected deficiency; possible benefit in severe deficiency (subgroup analysis)

VIOLET Trial (2019) - USA:

• 1,078 critically ill adults at risk of ARDS
• Intervention: Vitamin D3 540,000 IU single enteral dose vs placebo
• Primary outcome: 90-day mortality - NO DIFFERENCE (23.5% vs 20.6%, p=0.06 - actually trend toward harm)
• Secondary outcomes: No difference in hospital LOS, ventilator-free days, infections
• Trial stopped early for futility
• Interpretation: High-dose vitamin D does NOT improve outcomes

Synthesis: Both trials show that routine high-dose vitamin D supplementation does NOT improve mortality or other clinical outcomes in critically ill patients. The subgroup benefit in severe deficiency from VITdAL-ICU requires confirmation in dedicated trials.

---

Examiner: How would you respond to your colleague's suggestion?

Candidate: I would respectfully disagree with routine high-dose vitamin D for all ICU patients.

My Response:

"I understand the logic - vitamin D deficiency is common and associated with worse outcomes. However, the trial evidence doesn't support routine high-dose supplementation:

VITdAL-ICU showed no benefit for the primary outcome (hospital LOS) or mortality in the overall population with vitamin D deficiency.

VIOLET was even larger and also showed no mortality benefit - in fact, there was a trend toward harm, and the trial was stopped early for futility.

The association between vitamin D deficiency and poor outcomes may not be causal - low vitamin D may be a marker of illness severity rather than a therapeutic target.

Potential Harms of High-Dose Vitamin D:

• Hypercalcemia (especially with renal dysfunction)
• Hypercalciuria and nephrocalcinosis
• Cost and resource use without benefit

What I Do Recommend:

• Standard replacement (1,000-2,000 IU daily) for documented deficiency
• Check vitamin D levels in prolonged ICU stay, chronic disease, immunocompromised
• Consider higher supplementation only in severe deficiency (<30 nmol/L) based on VITdAL-ICU subgroup analysis, recognizing this is hypothesis-generating

The Bottom Line: The evidence doesn't support your suggestion, and we should practice evidence-based medicine. I'm happy to discuss the trials in more detail if you'd like."

---

Examiner: What general principles does this illustrate about interpreting observational associations?

Candidate: This is an excellent example of why observational associations don't prove causation and why we need randomized trials.

Key Principles:

1. Association is not causation: Just because vitamin D deficiency is associated with mortality doesn't mean correcting it improves outcomes. Vitamin D may be a marker (confounded by) underlying severity of illness.

2. Confounding: Sicker patients may have lower vitamin D for many reasons (inflammation, reduced synthesis, consumption). When we "correct" vitamin D, we don't correct the underlying illness.

3. Reverse causation: Critical illness may cause vitamin D deficiency (rather than deficiency causing poor outcomes).

4. Regression to the mean: Patients with very low values at baseline may improve naturally.

5. Subgroup analyses require confirmation: VITdAL-ICU found benefit in severe deficiency subgroup, but subgroup analyses are hypothesis-generating, not confirmatory. They can be false positives due to multiple comparisons.

6. Randomized controlled trials are essential: When observational data suggest benefit but RCTs are negative, we should trust the RCTs (assuming good methodology).

Other ICU Examples of This Phenomenon:

• Albumin supplementation: Low albumin associated with mortality, but SAFE trial showed no benefit of albumin replacement
• Tight glycemic control: Hyperglycemia associated with mortality, but intensive glucose control (NICE-SUGAR) increased mortality
• High-dose vitamin C: Observational associations with benefit, but LOVIT trial showed harm

This reinforces why critical appraisal of evidence is essential for ICU practice.